This brief review addresses subjective effects and adverse events after ecstasy, discusses possible therapeutic uses for MDMA and addresses potential neurotoxicity. It is unclear whether the review was written for a general audience of health care workers, for physicians or for pharmacologists. Generally, the review seems to suffer from a lack of thorough research in all areas addressed by the authors. Its strongest points are its coverage of the therapeutic potential of MDMA, including a discussion of concerns relating to psychological distress that might arise during therapeutic use. Its weakest point is its coverage of the history of MDMA, which contains several gross inaccuracies. The authors seem far more familiar with human pharmacokinetic studies than clinical studies of the subjective or physiological effects of MDMA, with none of the laboratory studies cited. At the same time, the review lacks a clear account of MDMA pharmacology or of the hypotheses put forth to explain its neurotoxicity. The authors state that large-scale prospective studies of long-term effects of ecstasy or MDMA are "prohibited" when this is not the case. Although it makes several interesting points, this scattershot review is probably better passed over in favor of more scholarly reviews such as Kalant (2001) and Hegadoren et al. (1999).